Scientists from Arthritis Research Canada found a significant drop in all-cause mortality and major adverse cardiovascular events in people from the group who took glucagon-like peptide-1 receptor agonists.
For those at high risk of diabetes, a threshold of four years of maintaining non-diabetic status could reduce the risk of death and cardiovascular complications.